"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 3 | 0 | 3 |
| 1998 | 6 | 3 | 9 |
| 1999 | 7 | 2 | 9 |
| 2000 | 5 | 1 | 6 |
| 2001 | 7 | 2 | 9 |
| 2002 | 4 | 6 | 10 |
| 2003 | 11 | 15 | 26 |
| 2004 | 12 | 6 | 18 |
| 2005 | 15 | 15 | 30 |
| 2006 | 17 | 10 | 27 |
| 2007 | 18 | 11 | 29 |
| 2008 | 18 | 13 | 31 |
| 2009 | 21 | 21 | 42 |
| 2010 | 20 | 22 | 42 |
| 2011 | 14 | 26 | 40 |
| 2012 | 21 | 17 | 38 |
| 2013 | 27 | 23 | 50 |
| 2014 | 29 | 19 | 48 |
| 2015 | 37 | 22 | 59 |
| 2016 | 34 | 30 | 64 |
| 2017 | 39 | 23 | 62 |
| 2018 | 43 | 27 | 70 |
| 2019 | 34 | 38 | 72 |
| 2020 | 42 | 26 | 68 |
| 2021 | 42 | 32 | 74 |
| 2022 | 2 | 34 | 36 |
| 2023 | 3 | 13 | 16 |
| 2024 | 13 | 28 | 41 |
| 2025 | 34 | 33 | 67 |
| 2026 | 15 | 4 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Appendiceal Adenocarcinoma Cytoreduction Outcomes and Perioperative Serum Tumor Marker Levels. JAMA Netw Open. 2026 May 01; 9(5):e2610569.
-
Integrated Spatial Analysis Reveals the Molecular Landscape of Ovarian Precancerous Lesions. Cancer Res. 2026 Apr 02; 86(7):1739-1752.
-
Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases. Neuro Oncol. 2026 Apr 01; 28(4):939-951.
-
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort. J Natl Cancer Inst. 2026 Apr 01; 118(4):746-750.
-
DICER1-mutated renal neoplasia: A series of 5 cases demonstrating the spectrum of cystic nephroma, Wilms tumor, and anaplastic sarcoma. Hum Pathol. 2026 Jun; 172:106110.
-
Translating ctDNA into cutaneous melanoma care: An international expert survey. Eur J Cancer. 2026 May 15; 239:116676.
-
Frequent synaptophysin expression in SMARCA4-deficient undifferentiated carcinoma of the oesophagus: a diagnostic pitfall with therapeutic implications. J Clin Pathol. 2026 Mar 19; 79(4):229-237.
-
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer. Nat Commun. 2026 Mar 12; 17(1).
-
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026 May 10; 44(14):1283-1295.
-
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. Nat Biomed Eng. 2026 Apr; 10(4):803-814.